23 August 2024
23 August 2024
Leo Pharma spent $36m to acquire Timber Pharmaceuticals last year, along with its lead dermatology asset TMB-001.
A FDA advisory committee (AdComm) is set to evaluate Lexicon’s Zynquista as an adjunct therapy for type 1 diabetes and chronic kidney disease.
Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the UK.
The updated mRNA Covid-19 vaccines of Pfizer and Moderna target the Omicron variant KP.2 strain.
Novartis holds the option for the acquisition of two development-ready programmes from Borealis.
The valuation of Rafael will be based on its cash value, marketable securities and other investments.
The acquisition of Echelon will bolster VION's capabilities in drug discovery and pre-clinical development.
The collaboration brings together CTI's clinical expertise with Crown Bioscience's preclinical and translational models.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
